349 related articles for article (PubMed ID: 18645710)
1. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.
Jakubowska J; Bohdanowicz-Pawlak A; Milewicz A; Szymczak J; Bednarek-Tupikowska G; Demissie M
Gynecol Endocrinol; 2008 Jul; 24(7):378-84. PubMed ID: 18645710
[TBL] [Abstract][Full Text] [Related]
2. [Study on the relationship between serum adiponectin and insulin resistance in women with polycystic ovary syndrome].
Yang XF; Ren FR; Guo SP
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):261-3. PubMed ID: 16759463
[TBL] [Abstract][Full Text] [Related]
3. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea.
Vgontzas AN; Trakada G; Bixler EO; Lin HM; Pejovic S; Zoumakis E; Chrousos GP; Legro RS
Metabolism; 2006 Aug; 55(8):1076-82. PubMed ID: 16839844
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
[TBL] [Abstract][Full Text] [Related]
5. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
6. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
7. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
8. [Correlations between adipocytokines and insulin resistance in women with polycystic ovary syndrome].
Li X; Li X; Huang HY; Ma D; Zhu MW; Lin JF
Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(37):2607-10. PubMed ID: 20137676
[TBL] [Abstract][Full Text] [Related]
9. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
10. Endothelial dysfunction in PCOS: role of obesity and adipose hormones.
Carmina E; Orio F; Palomba S; Longo RA; Cascella T; Colao A; Lombardi G; Rini GB; Lobo RA
Am J Med; 2006 Apr; 119(4):356.e1-6. PubMed ID: 16564785
[TBL] [Abstract][Full Text] [Related]
11. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D
Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
Trolle B; Flyvbjerg A; Kesmodel U; Lauszus FF
Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923
[TBL] [Abstract][Full Text] [Related]
13. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Alexandraki K; Piperi C; Aessopos A; Paterakis T; Katsikis I; Panidis D
Metabolism; 2007 Jan; 56(1):129-34. PubMed ID: 17161235
[TBL] [Abstract][Full Text] [Related]
14. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations.
Luque-Ramírez M; Escobar-Morreale HF
Horm Metab Res; 2010 Oct; 42(11):815-20. PubMed ID: 20730705
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein levels are unaffected by metformin during pretreatment and an IVF cycle in women with polycystic ovary syndrome.
Kjøtrød SB; Romundstad P; von Düring V; Sunde A; Carlsen SM
Fertil Steril; 2008 Mar; 89(3):635-41. PubMed ID: 17548076
[TBL] [Abstract][Full Text] [Related]
16. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
[TBL] [Abstract][Full Text] [Related]
17. Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy.
Diamanti-Kandarakis E; Economou FN; Livadas S; Tantalaki E; Piperi C; Papavassiliou AG; Panidis D
Kidney Blood Press Res; 2009; 32(1):24-31. PubMed ID: 19212122
[TBL] [Abstract][Full Text] [Related]
18. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
19. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
20. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome.
Thomann R; Rossinelli N; Keller U; Tirri BF; De Geyter C; Ruiz J; Kränzlin M; Puder JJ
Gynecol Endocrinol; 2008 Apr; 24(4):199-206. PubMed ID: 18382906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
